IL-17

North American Real-world EHR data of PsA & axSpA pts (n 2200 Ea.) found no higher rates of CVD (acute MI, CVA or revascularization) or solid cancers (breast, colorectal, lung, prostate) when comparing JAKi to either TNFi or IL-17i use (over 3 years). https://t.co/macjpWxdnY https://t.co/9gXiomU3YD

Links:

Dr. John Cush @RheumNow( View Tweet )
Antiviral prophylaxis is essential for HBsAg+ patients receiving cytokine inhibitors, given the high risk of reactivation. Metanalysis of 10 studies shows reactivation in 21% of HBsAg+ patients without prophylaxis vs 4.4% in HBsAg−/HBcAb+ patients. https://t.co/eHzIeA8uJK https://t.co/CmZw8C8ibn

Links:

Dr. John Cush @RheumNow( View Tweet )
SI.Sacroiliitis.AS_.jpg

Best of 2024: ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis

Jack Cush, MD

Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.

Read Article
GCA temporal artery

Drug-Free Remission in Giant Cell Arteritis is Uncommon

Jack Cush, MD

A Spanish retrospective registry study of patients with giant cell arteritis (GCA) found that 3-4 years after diagnosis, only 21% of patients with GCA successfully reached the sustained drug-free remission (SDFR). But if SDFR was achieved, the likelihood of experiencing recurrence was

Read Article
ACR24 IL-17 Panel Join Dr. Philip Mease, Dr. Brian Jaros and Dr. Peter Nash as they discuss key takeaways on IL-17 presentations and data presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/04bW7vaMTQ https://t.co/0rTglbW75u

Links:

Dr. John Cush @RheumNow( View Tweet )
psA.fil_.Hands_.jpg

ICYMI: Evaluation of Bimekizumab in PsA

Antoni Chan, MD, PhD

Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.

Read Article
RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

Jack Cush, MD

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
ACR24 IL-17 Topic Panel: Advancing Care with IL-17 Pathway Insights https://t.co/t9QQDYIrda

Links:

Dr. John Cush @RheumNow( View Tweet )

Anti IL-17 on Entheseal Biopsy in PsA Dr. Eric Dein reports on abstract 2586, presented at #ACR24 https://t.co/2JCFnB8HNq https://t.co/2MFCiNnvj2

Links:

Dr. John Cush @RheumNow( View Tweet )
How New Medications are Reframing Imaging Abnormalities in axSpA Bimekizumab (BKZ), a monoclonal antibody targeting IL-17A and IL-17F, was evaluated in the BE MOBILE 1 and 2 trials for non-radiographic and radiographic axSpA, respectively. It showed significant clinical… https://t.co/wJYh5XCVfw https://t.co/qZ2MnGVXXG
Dr. John Cush @RheumNow( View Tweet )
psA.fil_.Hands_.jpg

Novel and Emerging Therapies in Psoriatic Arthritis

Antoni Chan, MD, PhD

Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA. Three innovative

Read Article
PsA.Hands_.jpg

Up-front Secukinumab in PsA?

Richard Conway, MBBChBAO, PhD

We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the right patient. A study presented this week has

Read Article
Gender

Gender Differences in SpA

Sheila Reyes, MD

One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented addressed issues related to these differences particularly in the aspects of treatment response and disease activity.

Read Article
What is the effect of cs/bDMARDs on weight in #PsA? ⬇️Weight loss seen with: IL17i IL23i csDMARDs ⬆️Weight gain seen with: TNFi IL12/23i Important to consider #comorbidity & #BMI in management decisions in PsA Ab2639 #ACR24 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK

Links:

Eric Dein @ericdeinmd( View Tweet )
A#2585 PsABIOnd observ cohort study of IL23 (GUS) or IL17i 6 mo interim results of 686 pts PROs: PsAID-12 High Rx persistence at 6mo -94% on both Rx Comparable improvement in PsAID-12 - best results skin, discomfort 1/2 with clinically meaningful improvement #ACR24 @RheumNow https://t.co/TM1jwTRR7C

Links:

Eric Dein @ericdeinmd( View Tweet )
A#2586 EBIO study - secukinumab on entheseal bx in PsA. Compare b/l to 3+ mo on SEC Biopsy: change of entheseal cell composition on IL-17A Rx - decr Il-17A producing cells in responding pts Spatial transcriptomics - colocalizarjon of ILC2, CD200+ fibroblasts @RheumNow #ACR24 https://t.co/kMiqpBRxuE

Links:

Eric Dein @ericdeinmd( View Tweet )
Evaluation of Bimekizumab in PsA At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv
Dr. John Cush @RheumNow( View Tweet )
Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR

Links:

Richard Conway @RichardPAConway( View Tweet )
A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m

Links:

Eric Dein @ericdeinmd( View Tweet )
A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes Key findings: - Significant weight loss after starting IL17i, IL23i, and csDMARDs. - TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz

Links:

Mike Putman @EBRheum( View Tweet )
In a cohort of >17,000 European pts w/ axSpA: -bDMARD naïve pts starting TNFi or IL-17Ai were more likely to achieve LDA than TNF-experienced. -Higher time to achieve LDA and shorter durability in pts with prior TNFi use. Abst#1756 #ACR24 @RheumNow

Adela Castro @AdelaCastro222( View Tweet )

BE MOBILE 1 & 2: Bimekizumab resulted in improvement of SIJ MRI inflammation & structural lesions particularly after 16 wks of treatment and continued on until wk. 52. Supports addtl evidence of BKZ's winning streak in #axSpA @RheumNow #ACR24 abs1757 https://t.co/EUntQIuQC8

Links:

sheila @RHEUMarampa( View Tweet )
Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

Links:

Richard Conway @RichardPAConway( View Tweet )

Recent Blogs

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do!  Read Post

Best of 2022: Toss of a Coin - How do You Choose PsA Medication?

M. Elaine Husni, MD, MPH
Coin toss
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they?  Read Post
×